Recordati SpA (Recordati SpA) Short-Term Debt : $497 Mil (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Recordati SpA Short-Term Debt?

Recordati SpA's Short-Term Debt for the quarter that ended in Dec. 2023 was $497 Mil.

Recordati SpA's quarterly Short-Term Debt increased from Jun. 2023 ($427 Mil) to Sep. 2023 ($468 Mil) and increased from Sep. 2023 ($468 Mil) to Dec. 2023 ($497 Mil).

Recordati SpA's annual Short-Term Debt increased from Dec. 2021 ($262 Mil) to Dec. 2022 ($397 Mil) and increased from Dec. 2022 ($397 Mil) to Dec. 2023 ($497 Mil).

Recordati SpA Short-Term Debt Historical Data

The historical data trend for Recordati SpA's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recordati SpA Short-Term Debt Chart

Recordati SpA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

181.34

344.06

261.83

397.22

496.93

Recordati SpA Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															339.25	427.02	467.75	496.93	-

Recordati SpA Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Recordati SpA Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Recordati SpA's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Recordati SpA (Recordati SpA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Recordati SpA (OTCPK:RCDTF) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

RICFY:USA REC:Italy RECm:UK 0KBS:UK RER1:Germany

Address

Via Matteo Civitali 1, MIlan, ITA, 20148

Website

https://www.recordati.com

Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.

Recordati SpA (Recordati SpA) Headlines

From GuruFocus

Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa� (Osilodrostat) in Patients With Cushing's Disease in the European Journal of Endocrinology

By Business Wire Business Wire • 08-31-2022

ARS Pharmaceuticals and Recordati Announce Exclusive License for the Rights in Europe and additional countries for Neffy� (ARS-1; epinephrine nasal spray)

By PRNewswire PRNewswire • 09-22-2020

Recordati: Positive Results From the Phase III LINC-3 Study of Isturisa® (osilodrostat) for the Treatment of Cushing's Disease Published in Lancet Diabetes & Endocrinology

By Business Wire Business Wire • 07-28-2020

Recordati Rare Diseases Announces First European Launch of Isturisa® (osilodrostat)

By Business Wire Business Wire • 06-02-2020

Recordati: Isturisa® (Osilodrostat) Approved In The U.S.

By PRNewswire PRNewswire • 03-09-2020

Recordati Rare Diseases: Isturisa® (osilodrostat) Phase III LINC-4 Trial Meets Its Primary Endpoint in Cushing's Disease

By Business Wire Business Wire • 06-17-2020

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa� (Osilodrostat) in Patients With Cushing's Disease

By Business Wire Business Wire • 03-29-2022

Isturisa® Is Now Available as a Medical Treatment for Cushing's Syndrome in Germany

By Business Wire Business Wire • 07-16-2020